APASL2013 比较96周的疗效拉米夫定加诺阿德福韦联合治疗和单

StephenW

Abstract
比较96周的疗效拉米夫定加诺阿德福韦联合治疗和单用恩替卡韦HBeAg阳性CHB     
The Comparison of 96 Weeks Efficacy of Lamivudine Plus Adefovir de Novo Combination Therapy and Entecavir Monotherapy for HBeAg-positive CHB     
     
Jie Yan, Na Ren, Hao-Dong Cai, Wen Xie, Jun Cheng
Beijing Ditan Hospital, Capital Medical University, Beijing, China

Objective: Evaluated the efficacy and safety of lamivudine(LAM) and adefovir dipivoxil(ADV) de novo combination therapy versus entecavir(ETV) monotherapy in the treatment of HBeAg-positive chronic hepatitis B (CHB) at 96 week.
Methods: 50 patients of CHB were enrolled into the clinical cohort study. They were divided into 2 treatment groups according to patients desire, one is the group of ETV monotherapy, and the other is the group of LAM and ADV combined treatment.
Results: After 96 weeks antivirus treatment, 19 patients (86.4%) of the ETV group achieved complete virological response, and the combined treatment group were only 9 cases (42.9%), the results had significant differenc(P = 0.003, Table 1, Figure 1); all the patients of the two groups have achieved significant improvement in the liver biochemical responses; the aspects of the patients in two groups those that the HBeAg、HBsAg converting to negative, the serologic conversion of HBe series and the other immune control indicators do not obviously change(Table 2). There were no patients of two groups happened the virological breakthrough or HBV DNA bounce during the period of 96 weeks of treatment and the follow-up. During the period of 96 weeks treatment and the follow-up no adverse reaction happened in the patients of the two groups. The results about the renal function of the patients in the baseline point and the 96th week are all in the normal range in two groups , and have no significant difference before and after the treatment(Table 3).
Conclusion: In those CHB patients of HBeAg-positive, after 96 weeks antiviral therapy, the rates of the virological response which using the method of application of ETV monotherapy were significantly higher than of combined application of LAM and ADV.


Assigned speakers:
Prof. Jun Cheng, Beijing Ditan Hospital , Beijing , China

Assigned in sessions:
07.06.2013, 08:30-17:30, PT-4, HEP B Clinical, Exhibition Hall
in sessions:
07.06.2013, 08:30-17:30, PT-4, HEP B Clinical, Exhibition Hall

StephenW

目的：评估拉米夫定（LAM）和阿德福韦酯（ADV）的重新组合与恩替卡韦（ETV）单药治疗HBeAg阳性慢性乙型肝炎（CHB）在96周治疗的有效性和安全性。
方法：50例慢性乙型肝炎患者进入临床队列研究。他们被分成2个治疗组根据患者的愿望，一个是ETV单药治疗组，其他组的LAM和ADV合并的治疗。
结果：96周后抗病毒治疗，19例（86.4％），ETV组实现了完整的病毒学应答，联合治疗组只有9例（42.9％），结果有显着差异（P = 0.003，表1，图1）;两组所有患者都取得了显着的改善肝脏生化反应，两组患者在那些方面，e抗原，乙肝表面抗原转换为负，HBE系列的血清学转换和其他免疫控制指标没有明显变化（见表2）。有没有两组患者在为期96周的治疗和后续发生病毒学突破或HBV DNA反弹。在96周治疗期间的后续无不良反应的两个组中的患者发生。有关的肾功能的患者中的基准点，并在第96周的结果都在正常范围内两组，并没有显着的差异之前和之后的处理（表3）。
结论：在那些HBeAg阳性CHB患者，抗病毒治疗96周后，使用该方法应用ETV单药治疗的病毒学应答率明显高于LAM和ADV联合应用。

MP4

两组的HBeAg阴转、HBe血清学转换、HBsAg阴转等免疫控制指标均无明显变化?

StephenW

回复 MP4 的帖子

写的不好的摘要.